Recent advances in the treatment of myeloma
| Recent advances . |
|---|
| Triplet induction with VRD that combines a proteasome inhibitor and an immunomodulatory drug improves OS14 |
| ASCT improves PFS in the context of modern therapy15 |
| Posttransplant maintenance (lenalidomide in standard-risk myeloma and bortezomib in intermediate- and high-risk myeloma) improves OS16-18 |
| Identification and approval of new effective drugs |
| • Carfilzomib (irreversible proteasome inhibitor)19 |
| • Pomalidomide (new immunomodulatory analog of lenalidomide)20 |
| • Panobinostat (deacetylase inhibitor)21 |
| • Elotuzumab (anti-SLAMF7 monoclonal antibody)22 |
| • Daratumumab (anti-CD38 monoclonal antibody)23,24 |
| • Ixazomib (oral proteasome inhibitor)25 |
| Identification of investigational drugs with single-agent activity26 |
| • Isatuximab (anti-CD38 monoclonal antibody) |
| • Marizomib (proteasome inhibitor) |
| • Oprozomib (oral proteasome inhibitor) |
| • Filanesib (kinesin spindle protein inhibitor) |
| • Dinaciclib (cyclin-dependent kinase inhibitor) |
| • Venetoclax (selective BCL-2 inhibitor) |
| • LGH-447 (pan PIM kinase inhibitor) |
| Recent advances . |
|---|
| Triplet induction with VRD that combines a proteasome inhibitor and an immunomodulatory drug improves OS14 |
| ASCT improves PFS in the context of modern therapy15 |
| Posttransplant maintenance (lenalidomide in standard-risk myeloma and bortezomib in intermediate- and high-risk myeloma) improves OS16-18 |
| Identification and approval of new effective drugs |
| • Carfilzomib (irreversible proteasome inhibitor)19 |
| • Pomalidomide (new immunomodulatory analog of lenalidomide)20 |
| • Panobinostat (deacetylase inhibitor)21 |
| • Elotuzumab (anti-SLAMF7 monoclonal antibody)22 |
| • Daratumumab (anti-CD38 monoclonal antibody)23,24 |
| • Ixazomib (oral proteasome inhibitor)25 |
| Identification of investigational drugs with single-agent activity26 |
| • Isatuximab (anti-CD38 monoclonal antibody) |
| • Marizomib (proteasome inhibitor) |
| • Oprozomib (oral proteasome inhibitor) |
| • Filanesib (kinesin spindle protein inhibitor) |
| • Dinaciclib (cyclin-dependent kinase inhibitor) |
| • Venetoclax (selective BCL-2 inhibitor) |
| • LGH-447 (pan PIM kinase inhibitor) |
BCL-2, B-cell lymphoma 2; OS, overall survival; PFS, progression-free survival; PIM, proto-oncogene serine/threonine-protein; SLAMF-7, signaling lymphocytic activation molecule F7.